Regarding patient #3, the one who discontinued Leronlimab because of an unrelated IV issue - my best guess as to why this patient cannot continue with the Leronlimab injections is that the clinical trial mentions carboplatin (which is likely delivered by IV) in conjunction with Leronlimab, so if carboplatin can no longer be delivered by IV because of a port issue, then presumably the clinical trial protocols would not permit further Leronlimab injections by itself.